Related references
Note: Only part of the references are listed.The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
K. Reich et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J. Edwards et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Alon D. Levin et al.
JOURNAL OF CROHNS & COLITIS (2016)
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo et al.
JOURNAL OF RHEUMATOLOGY (2016)
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
Paolo Gisondi et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Apremilast: A Review in Psoriasis and Psoriatic Arthritis
Emma D. Deeks
DRUGS (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE
K. A. Papp et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Etiology and Pathogenesis of Psoriasis
Wolf-Henning Boehncke
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2015)
The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)
Peter H. Schafer et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets
F. Ahmad et al.
ORAL DISEASES (2015)
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
P. H. Schafer et al.
CELLULAR SIGNALLING (2014)
Loss of Response to Anti-Tumor Necrosis Factors: What Is the Next Step?
Shomron Ben-Horin
DIGESTIVE DISEASES (2014)
Apremilast: First Global Approval
Raewyn M. Poole et al.
DRUGS (2014)
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar et al.
GUT (2014)
Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III)
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2014)
Phosphodiesterase 4 and its inhibitors in inflammatory diseases
S.-L.Catherine Jin et al.
Biomedical Journal (2014)
Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents
Emily Yiping Gan et al.
BIODRUGS (2013)
Phosphodiesterase 4-targeted treatments for autoimmune diseases
Neal Kumar et al.
BMC MEDICINE (2013)
Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study
Vibeke Strand et al.
JOURNAL OF RHEUMATOLOGY (2013)
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
K. A. Papp et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice
Florian Rieder et al.
PLOS ONE (2013)
Pharmacophore Modeling and Virtual Screening for the Discovery of New type 4 cAMP Phosphodiesterase (PDE4) Inhibitors
Miaomiao Niu et al.
PLOS ONE (2013)
Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study
Georg Schett et al.
ARTHRITIS AND RHEUMATISM (2012)
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Kim Papp et al.
LANCET (2012)
Review article: loss of response to anti-TNF treatments in Crohn's disease
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
MEDICAL PROGRESS Ulcerative Colitis
Silvio Danese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
P. H. Schafer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Pooneh Salari-Sharif et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Matthieu Allez et al.
JOURNAL OF CROHNS & COLITIS (2010)
Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown
Miles D. Houslay
TRENDS IN BIOCHEMICAL SCIENCES (2010)
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases
Georg Schett et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2010)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease
J. N. Gordon et al.
JOURNAL OF CROHNS & COLITIS (2009)
Inhibition of cAMP Degradation Improves Regulatory T Cell-Mediated Suppression
Tobias Bopp et al.
JOURNAL OF IMMUNOLOGY (2009)
Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor
Hon-Wah Man et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease
Leila Gobejishvili et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2008)
Cyclic AMP - Master regulator of innate immune cell function
Carlos H. Serezani et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2008)
An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
A. B. Gottlieb et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Tetomilast Suppressed Production of Proinflammatory Cytokines from Human Monocytes and Ameliorated Chronic Colitis in IL-10-Deficient Mice
Hitoshi Ichikawa et al.
INFLAMMATORY BOWEL DISEASES (2008)
A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells
Ruihong Ma et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2008)
NF-κB in inflammatory bowel disease
I. Atreya et al.
JOURNAL OF INTERNAL MEDICINE (2008)
Induction and effector functions of TH17 cells
Estelle Bettelli et al.
NATURE (2008)
Phosphodiesterase inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease
Ali Keshavarzian et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Cyclic adenosine monophosphate is a key component of regulatory T cell mediated suppression
Tobias Bopp et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Epithelial NEMO links innate immunity to chronic intestinal inflammation
Arianna Nenci et al.
NATURE (2007)
A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis
Stefan Schreiber et al.
GASTROENTEROLOGY (2007)
Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis
S Videla et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide
HJ Kwak et al.
INFLAMMATION RESEARCH (2005)
Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-κB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation
HJ Kwak et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Phosphodiesterase-4 as a therapeutic target
MD Houslay et al.
DRUG DISCOVERY TODAY (2005)
Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract
GS Baillie et al.
FEBS LETTERS (2005)
The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro
NA Jones et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2005)
Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: Implications in angiogenesis
SJ Netherton et al.
MOLECULAR PHARMACOLOGY (2005)
Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-{2-(3,4-bis-difluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor
D Claveau et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases
W Richter et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors
L Favot et al.
THROMBOSIS AND HAEMOSTASIS (2003)
The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice
F Loher et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization
MD Houslay et al.
BIOCHEMICAL JOURNAL (2003)
Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs)
W Richter et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Cyclic nucleotide research - still expanding after half a century
JA Beavo et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation
MJ Sanz et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity
N Diaz-Granados et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
